Armed with $36M A round, Johns Hop­kins spin­out Neu­raly heads to PhI Parkin­son's tri­al

A start­up com­pa­ny spun out of Johns Hop­kins says it’s been able to slow the pro­gres­sion of Parkin­son’s dis­ease in mice mod­els — and with a fresh in­fu­sion of cash, the com­pa­ny is tak­ing the pro­gram in­to hu­man tri­als.

The start­up, called Neu­raly, was launched back in 2016 out of the labs of Ted Daw­son, a pro­fes­sor of neu­rode­gen­er­a­tive dis­eases at Johns Hop­kins. And now, Neu­raly has scored the fi­nan­cial back­ing it need­ed to move in­to the clin­ic. The start­up’s par­ent group, D&D Phar­mat­e­ch, led a $36 mil­lion in a Se­ries A round for Neu­raly, and were joined by a group of Ko­re­an in­vestors in­clud­ing Smi­le­gate In­vest­ment and In­ter­Vest, among oth­ers. In­ter­est­ing­ly, many of these in­vest­ment firms al­so put down cash for D&D Phar­mat­e­ch just months ago in the par­ent com­pa­ny’s own Se­ries A round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER